Blog Page


QT Imaging, the University of Illinois, and the Sunnybrook Research Institute Receive $3.1 Million National Cancer Institute Grant for Breast Cancer Treatment Monitoring – Yahoo Finance

The QTscan to be used to improve the assessment of tumor response in neo-adjuvant chemotherapy treatments
NOVATO, Calif., Oct. 13, 2022 /PRNewswire/ — QT Imaging, Inc., a medical imaging company focused on the development and clinical adoption of novel products for breast cancer imaging, today announced the award of a five-year National Cancer Institute grant to study the progress of neo-adjuvant therapy for women with breast cancer using the QTscan. The grant will use QT Imaging’s Breast Scanning System enhanced with reflection back-scatter algorithms developed by the University of Illinois to assess tumor response to treatment in days rather than weeks or months. The study is a collaboration of Dr. James Wiskin, Principal Scientist at QT Imaging, Prof. Michael Oelze in the Department of Electrical and Computer Engineering at the University of Illinois Urbana-Champaign (UIUC), and Dr. Gregory Czarnota from the Radiation Oncology Department of the Sunnybrook Research Institute in Toronto, Canada.
Only some women benefit from early-stage chemotherapy for breast cancer. While there are tests to determine who is likely to benefit, there are no FDA-approved tests to determine if applying these early treatments is working other than long-term repeated standard medical imaging. This grant project is designed to use more accurate imaging technology and software to improve the assessment of the efficacy of these neo-adjuvant chemotherapy treatments. The QT Imaging system does not use ionizing radiation or contrast agents and can be safely used to image the breasts of women undergoing neo-adjuvant chemotherapy treatments at repeated short intervals to accurately (+ 0.2%) measure tumor volumes and quantify tumor state based on their sound speed and backscatter properties.
“Currently, if a breast cancer patient does not respond to the initial chemotherapy regimen, there may be little recourse for adjusting the therapy regimen to the benefit of the patient because the lack of response is not identified early on during the course of therapy. By identifying response or lack of response early on during the course of therapy, physicians will be able to adjust therapy approaches and thereby improve outcomes,” said Dr. Michael Oelze.
“We are encouraged by the continued high performance of QT imaging in breast imaging, and these results will demonstrate the clinical value of QT’s low frequency transmitted sound volography as a high-resolution imaging modality, specifically in the context of tumor monitoring and response to neo-adjuvant chemotherapy. We gratefully acknowledge the NIH-NCI in their generous acknowledgement of the potential of this unique confluence of technologies with Dr. Czarnota and Dr. Oelze, recognized leaders in their fields,” said Dr. James Wiskin, Principal Scientist at QT Imaging.
About QT Imaging, Inc.
QT Imaging™ is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner. The company’s clinical trials have been conducted at prestigious institutions in the US and Europe, and the National Institutes of Health (NIH) has supported the development of the technology with over $18 MM in grants.
The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The QT scanner software also calculates the breast fibroglandular volume and total breast volume.  The device is not intended to be used as a replacement for screening mammography. FDA 510k K162372 and K220933
For more information visit qtimaging.com.
Mikie Price
[email protected]
Michaela Kalff
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/qt-imaging-the-university-of-illinois-and-the-sunnybrook-research-institute-receive-3-1-million-national-cancer-institute-grant-for-breast-cancer-treatment-monitoring-301648550.html
On and off "manufacturing delays" at Teva Pharmaceutical are the reason for the Adderall shortage that has been going on in America in recent weeks, the U.S. Food and Drug Administration said this week. Amphetamine mixed salts, including Adderall, are FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The FDA says that while there is a shortage, there are alternative therapies, including the extended-release version of amphetamine mixed salts that are available to health care professionals.
A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are hoping they will persuade more Americans to get the updated shot.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Inovio Pharmaceuticals Inc (NASDAQ: INO) announced interim results from an ongoing Phase 1/2 trial evaluating INO-3107 for HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. RRP is caused primarily by HPV types 6 and/or 11 characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgi
U.K. drug maker GSK reported partial results from a respiratory syncytial virus vaccine trial that appear to be at least competitive with Pfizer's latest data.
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
Shares of Novavax Inc. (NVAX) were down 3.4% in premarket trading on Thursday after the company said its combination COVID-19 vaccine and flu shot candidate generated an immune response in a Phase 1/2 clinical trial. Novavax also said that the safety and tolerability of the combination vaccine was consistent with getting a standalone COVID-19 vaccine or flu shot, and it plans to begin a confirmatory Phase 2 clinical trial this year. Novavax’s stock has tumbled 85.8% this year, while the S&P 500 (SPX) has declined 24.7%.
The change represents Gilead's focus on research, now concentrated on the south section of its 72-acre Foster City campus.
This health stock is up over 9% for the week and within 3% of a buy point on the chart. Shares soared on news of its obesity treatment.
A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura.
Investors often favor that industry during tough times because its earnings are less at risk — patients can't do without the products these companies sell. Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon. Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.
At an event in Boston on Wednesday, CEO Karen Lynch talked of the strategy around recent and planned acquisitions.
The difference between the common cold, flu and COVID-19
Sangamo Therapeutics Inc (NASDAQ: SGMO) has announced updated preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), a gene therapy candidate for Fabry disease. Recently, Sangamo and Pfizer Inc (NYSE: PFE) reopened enrollment in phase 3 AFFINE study hemophilia A gene therapy trial after pausing it due to some patients experiencing blood clotting protein factor VIII activity greater than 150%. These latest data show that all nine patients treated in the
Pharmaceutical manufacturers Moderna and Merck are partnering together to develop a cancer vaccine.
Some people answered “I wanted to exercise my freedom to do what I want,” according to the study.
“While most people recover quickly and completely after infection with COVID-19, some people develop a wide variety of long-term problems,” lead study author Jill Pell said.
Three years after emerging from stealth with plans to use RNA to silence disease-causing genes, Atlas Venture spinout Triplet Therapeutics is winding down its operations. Here's why.
While it’s common knowledge that there are many benefits of exercise, the good news is you don’t need to perform high-intensity workouts to reap the mental health rewards. According to a new study, the effects of physical activity on brain volume were most pronounced at low physical activity …
White House predicts rise in COVID cases this coming winter


× How can I help you?